

Aerocrine

Aerocrine AB announces change in the board of directors

December 12, 2014

Solna (Sweden) – December 12, 2014 – Aerocrine AB (Nasdaq Stockholm: AERO) today announces that board member Staffan Lindstrand has resigned from the board of directors effective immediately.

For more information, please contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368 0336

About Aerocrine

Aerocrine AB is a medical product company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. For more information, please visit www.aerocrine.com and www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 5:00 p.m. on December 12, 2014